Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02552888 · ClinicalTrials.gov registry record · Phase 2
Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial
A Phase 2 study, sponsored by Tulane University.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT02552888: Completed Phase 2 study, sponsored by Tulane University.
NCT02552888 is a Phase 2 study that has completed, run by Tulane University. The registered enrollment target is 70 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02552888, a Phase 2 study, has completed, sponsored by Tulane University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The proposed randomized controlled trial will test the safety and efficacy of combination therapy with sodium nitrite and isoquercetin on endothelial function and inflammation among patients with chronic kidney disease.
Primary Outcome
FMD was measured using high resolution ultrasound on the brachial artery. FMD was calculated as the maximal percentage change in vessel size during hyperemia . The mean changes between baseline, 6 weeks and 12 weeks in FMD with 95% CI were calculated using linear mixed effects model.
Interventions
- DRUG Immediate release sodium nitrite
- DIETARY_SUPPLEMENT Isoquercetin
- OTHER placebos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
What the finished NCT02552888 record still lists
NCT02552888 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 3 interventions - of which Immediate release sodium nitrite is the first listed.
NCT02552888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02552888 about?
NCT02552888 is a clinical study titled "Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial". The proposed randomized controlled trial will test the safety and efficacy of combination therapy with sodium nitrite and isoquercetin on endothelial function and inflammation among patients with chronic kidney disease.
What is the current status of trial NCT02552888?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2016-03. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02552888?
The interventions under investigation include: Immediate release sodium nitrite (DRUG), Isoquercetin (DIETARY_SUPPLEMENT), placebos (OTHER).
Who is sponsoring clinical trial NCT02552888?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02552888's enrollment target sits among peer trials
70 937th of 2000 higher than 1,036 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia